Fiche du document
2008
- doi: 10.1016/j.burns.2007.11.003
- issn: 0305-4179
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.burns.2007.11.003
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/18395988
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0305-4179
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A54CC210B3960
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Nebramycin factor 6Citer ce document
D. Bracco et al., « Pharmacokinetic variability of extended interval tobramycin in burn patients. », Serveur académique Lausannois, ID : 10.1016/j.burns.2007.11.003
Métriques
Partage / Export
Résumé
BACKGROUND: Aminoglycosides are mandatory in the treatment of severe infections in burns. However, their pharmacokinetics are difficult to predict in critically ill patients. Our objective was to describe the pharmacokinetic parameters of high doses of tobramycin administered at extended intervals in severely burned patients. METHODS: We prospectively enrolled 23 burned patients receiving tobramycin in combination therapy for Pseudomonas species infections in a burn ICU over 2 years in a therapeutic drug monitoring program. Trough and post peak tobramycin levels were measured to adjust drug dosage. Pharmacokinetic parameters were derived from two points first order kinetics. RESULTS: Tobramycin peak concentration was 7.4 (3.1-19.6)microg/ml and Cmax/MIC ratio 14.8 (2.8-39.2). Half-life was 6.9 (range 1.8-24.6)h with a distribution volume of 0.4 (0.2-1.0)l/kg. Clearance was 35 (14-121)ml/min and was weakly but significantly correlated with creatinine clearance. CONCLUSION: Tobramycin had a normal clearance, but an increased volume of distribution and a prolonged half-life in burned patients. However, the pharmacokinetic parameters of tobramycin are highly variable in burned patients. These data support extended interval administration and strongly suggest that aminoglycosides should only be used within a structured pharmacokinetic monitoring program.